scanX
Shilpa Medicare

Shilpa Medicare

356.00
-1.20
(-0.34%)
hide
Key Fundamentals
Add Ratio
Market Cap
6,986.20 Cr
EPS
8.04
PE Ratio
62.71
Dividend Yield
0.14 %
Industry
Healthcare
52 Week High
1,000.00
52 Week Low
277.50
PB Ratio
2.94
Debt to Equity
0.36
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Shilpa Medicare Promoters Enter Inter-se Agreement for Securities Transfer Framework3 days ago
Promoters of Shilpa Medicare Limited entered into an Inter-se Agreement on October 16, 2025, establishing terms for transfer and sale of securities among the promoter group. The agreement covers restrictions on securities transfer, Right of First Refusal provisions, Drag-Along Rights for the Bhutada Group, and liabilities related to personal guarantees for company loans. The promoter group collectively holds 78,496,648 shares representing 40.14% of the company. The agreement involves 21 promoters and promoter group members from the Bhutada and Innani families. Shilpa Medicare Limited is not a party to this agreement, which formalizes inter-se arrangements without altering overall promoter group shareholding or control of the company.
neutral
Shilpa Medicare Gets NSE Approval for Promoter Group Reclassification Worth 4.09% ShareholdingSep 26, 2025
Shilpa Medicare Limited received approval from the National Stock Exchange for reclassifying two promoter group shareholders to public category. Suraj Kumar Inani, holding 39,20,695 shares (4.01%), and Priya Inani, holding 80,696 shares (0.08%), have been reclassified from promoter group to public shareholders. The total reclassification represents 40,01,391 shares or 4.09% of the company's shareholding structure. The approval was granted under Regulation 31A of SEBI (LODR) Regulations, 2015, following the company's application submitted in August 2025.
positive
Shilpa Medicare Receives European Authorization for Generic Rivaroxaban Orodispersible FilmsSep 22, 2025
Shilpa Medicare Limited received Initial Authorization from the European Medicine Agency for Rivaroxaban 10 mg, 15 mg, and 20 mg Orodispersible Films, a generic version of Bayer AG's Xarelto. The approval covers the company's manufacturing facility in Dabaspet, Bengaluru. The anticoagulant medicine is used to treat deep vein thrombosis, pulmonary embolism, and prevent atherothrombotic events in adults. Shilpa's product is bioequivalent to Xarelto and represents the only Rivaroxaban in orodispersible film form, designed for patient comfort particularly in geriatric patients. The European market for oral Rivaroxaban formulations is valued at USD 2.5 billion. This marks the third approval of a prescription oral mouth dissolving film product in European markets from the Bengaluru facility.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,679.10
#1 3,98,049.70
38.75
#1 54,729.00
9.71
#1 10,980
-19.84
61.71
Divis Laboratories
6,621.50
1,75,222.50
76.19
9,712.00
18.67
2,191
26.74
72.60
Cipla
1,577.60
1,26,768.90
23.67
28,409.50
7.12
5,291
9.88
60.63
Torrent Pharmaceuticals
3,584.30
1,19,599.80
60.49
11,539.40
6.99
1,911
19.91
53.74
Dr Reddys Laboratories
1,255.90
1,03,508.80
#1 18.25
33,741.20
16.73
5,725
1.26
48.97
Mankind Pharma
2,476.60
1,01,344.60
53.48
12,744.20
#1 20.90
2,007
-18.14
47.04
Zydus Life Science
987.65
99,073.80
21.09
23,511.00
18.55
4,615
2.60
45.37
Lupin
1,940.00
89,121.90
23.79
22,909.50
13.74
3,306
#1 51.64
46.82
Alkem Laboratories
5,581.50
66,047.70
28.61
13,458.30
3.70
2,216
21.39
63.11
Aurobindo Pharma
1,101.00
64,254.10
19.04
32,345.60
9.43
3,484
-10.24
50.87

Automatic Screeners on ScanX

Community
Support 1 Breached
Growth Rate
Revenue Growth
12.92 %
Net Income Growth
144.69 %
Cash Flow Change
-3.29 %
ROE
85.96 %
ROCE
23.15 %
EBITDA Margin (Avg.)
19.23 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
168
151
177
202
203
168
219
186
231
174
209
191
241
203
192
177
203
163
296
241
229
289
288
200
215
239
306
278
346
269
267
266
266
262
315
289
300
302
349
321
341
328
Expenses
129
120
137
158
146
139
161
151
171
133
155
159
189
149
128
153
163
132
223
163
175
158
210
171
182
206
243
228
268
241
253
231
227
214
255
222
222
223
258
239
282
231
EBITDA
39
31
40
44
58
30
58
35
60
40
54
31
53
54
64
24
41
31
73
78
54
131
78
29
33
33
62
50
78
28
14
34
39
48
60
67
79
80
91
82
59
97
Operating Profit %
23 %
19 %
21 %
21 %
26 %
16 %
23 %
17 %
23 %
20 %
24 %
14 %
20 %
25 %
21 %
12 %
19 %
18 %
23 %
31 %
21 %
29 %
25 %
11 %
12 %
13 %
18 %
16 %
21 %
8 %
4 %
12 %
14 %
18 %
19 %
23 %
24 %
24 %
25 %
25 %
15 %
28 %
Depreciation
5
5
6
6
6
7
7
8
8
9
8
9
11
10
10
11
11
11
11
11
12
12
13
14
15
18
19
21
22
22
23
24
26
27
28
27
27
27
28
29
29
29
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
4
4
5
9
10
12
10
9
10
14
18
18
18
23
26
24
24
26
12
15
19
Profit Before Tax
32
25
34
37
50
22
50
27
51
31
46
22
41
43
53
11
29
19
62
65
42
115
61
11
8
5
32
19
46
-4
-22
-8
-4
3
9
14
28
29
37
42
15
50
Tax
10
7
12
10
12
8
12
10
14
9
12
5
10
10
11
-1
6
4
11
11
8
29
16
3
1
4
12
10
17
-6
-4
-1
4
2
8
10
3
15
19
10
1
3
Net Profit
22
18
22
27
38
14
38
17
37
22
34
16
31
33
42
12
23
15
51
55
34
86
45
8
8
2
20
10
30
2
-19
-7
-8
1
2
5
25
14
18
32
15
47
EPS in ₹
5.86
4.70
6.05
3.60
4.27
1.92
4.97
2.03
4.33
2.77
4.21
2.29
3.79
4.28
5.22
1.46
2.93
1.93
6.23
6.75
4.24
10.59
5.57
0.94
0.96
0.19
2.45
1.13
3.40
0.10
-2.15
-0.76
-0.93
0.14
0.19
0.53
2.82
1.46
1.83
3.25
1.48
4.79
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Fixed Assets
316
393
492
534
558
650
1,111
1,342
1,368
1,385
1,418
Current Assets
328
354
730
672
545
624
903
887
770
877
986
Capital Work in Progress
222
92
141
210
429
666
541
506
655
719
822
Investments
65
94
253
140
2
11
21
34
43
40
35
Other Assets
302
352
587
615
621
662
959
993
838
950
1,037
Total Liabilities
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Current Liabilities
189
222
237
266
253
411
604
612
784
693
674
Non Current Liabilities
154
67
251
154
167
257
561
453
345
600
273
Total Equity
561
642
984
1,080
1,190
1,322
1,468
1,811
1,774
1,800
2,364
Reserve & Surplus
539
632
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
2,363
Share Capital
8
8
8
8
8
8
8
9
9
9
10
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
9
3
93
-26
-40
10
79
-98
-7
13
-3
Investing Activities
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
-198
Operating Activities
69
129
38
45
147
124
47
105
180
137
132
Financing Activities
136
-20
313
-61
10
176
436
83
46
47
63
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
53.25 %
53.25 %
53.25 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
44.39 %
44.39 %
44.33 %
44.23 %
44.23 %
44.23 %
44.23 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.60 %
8.52 %
0.00 %
0.00 %
9.08 %
9.58 %
9.90 %
10.97 %
11.20 %
10.92 %
DIIs
2.95 %
2.05 %
2.29 %
2.15 %
2.12 %
1.01 %
1.01 %
1.01 %
0.61 %
0.54 %
0.00 %
0.41 %
0.06 %
1.59 %
6.13 %
7.61 %
8.18 %
8.27 %
7.55 %
7.46 %
7.67 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.80 %
17.89 %
19.49 %
18.23 %
18.57 %
20.12 %
20.51 %
18.95 %
21.85 %
24.05 %
26.82 %
25.40 %
25.45 %
27.64 %
24.54 %
24.69 %
23.94 %
24.40 %
24.43 %
23.21 %
23.34 %
Others
27.01 %
26.81 %
24.97 %
29.61 %
29.31 %
28.87 %
28.47 %
30.03 %
27.52 %
25.40 %
23.17 %
15.59 %
15.96 %
20.75 %
24.94 %
14.23 %
13.96 %
13.21 %
12.83 %
13.90 %
13.84 %
No of Share Holders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034
50,108
48,636
52,065

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.6 0.6 0.7 1 1.1 1.1 1.1 0.00 0.00 1
Dividend Yield (%) 0.19 0.26 0.41 0.82 0.66 0.55 0.96 0.00 0.00 0.28

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Sept 2021 DIVIDEND Dividend
₹ 1.10 /share
 20 Sept 2021 257.93 277.10
20 Sept 2022 DIVIDEND Dividend
₹ 1.10 /share
 19 Sept 2022 210.73 187.95
17 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 17 Sept 2024 353.38 447.35
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 421.15 437.78
10 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 10 Feb 2025 347.75 365.43
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 26 May 2025 353.98 390.75
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Aug 2025 850.40 870.20
17 Sept 2025 DIVIDEND Dividend
₹ 1.00 /share
 17 Sept 2025 390.75 413.13
23 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 23 Sept 2025 870.20 408.63
03 Oct 2025 BONUS Bonus
1:1
 03 Oct 2025 410.33 390.50

Announcements

Intimation Under Regulation 30 Read With Regulation 30A And Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20189 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Shareholder Meeting / Postal Ballot-Notice of Postal BallotOct 07, 2025
Announcement under Regulation 30 (LODR)-AllotmentOct 06, 2025
NSE - In Principle Approval For Bonus IssueSep 29, 2025
Promoter Reclassificion - NOC From BSESep 27, 2025
In-Principle Approval For Bonus IssueSep 26, 2025
Promoter Reclassificaiton - NOC From NSESep 26, 2025
Closure of Trading WindowSep 26, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 24, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Announcement under Regulation 30 (LODR)-CessationSep 23, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 23, 2025
Initial Authorization For Rivaroxaban Orodispersible Films From EuropeSep 22, 2025
Reg. 34 (1) Annual Report.Sep 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Dispatch Of Letters To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent/ Depository ParticipantsAug 28, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 ("SEBI Listing Regulations")Aug 28, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 ("SEBI Listing Regulations")Aug 28, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesAug 26, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2025
Annual ReportAug 26, 2025
AGM NoticeAug 26, 2025
Intimation Of Revised Record Date For Bonus IssueAug 22, 2025
Intimation For Participation In Investor ConferenceAug 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Intimation Of Submission Of Application For Reclassification Of Promoter/ Promoter Group From Promoter Group Category To "Public Category Pursuant To Regulation 31A (8) (C) Of SEBI (LODR) Regulations 2015Aug 13, 2025
Intimation Under 31A Of The SEBI (LODR) Regulations 2015 For Reclassification From Promoter/Promoter Group To Public CategoryAug 13, 2025
Corporate Action-Board recommends Bonus IssueAug 13, 2025
Record Date Of Bonus IssueAug 13, 2025
Record Date For The Purpose Of DividendAug 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Results - Financial ResultsAug 13, 2025
Board Meeting Outcome for OutcomeAug 13, 2025
Redemption Of Non-Convertible Debentures (NCD) By Shilpa Pharma Lifesciences Limited (SPL)Aug 12, 2025
Shilpa Announces Approval Of Nor Ursodeoxycholic Acid Tablets 500 Mg For The Treatment Of Non-Alcoholic Fatty Liver Disease In IndiaAug 09, 2025
Update on board meetingAug 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Board Meeting Intimation for Consider And Approve Unaudited Financial Results Of The Company For The Quarter Ended June 30 2025Aug 05, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 24, 2025
Intimation Pursuant To Receipt Of Reclassification Application From Persons Related To PromotersJul 17, 2025
EIR From USFDA For Shilpa Medicare Ltd. Unit VI Bengaluru.Jul 16, 2025
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 10, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementJul 05, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Shilpa Pharma Lifesciences Limited Unit-1 ANVISA Audit From BrazilJul 04, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 02, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementJun 28, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Innovation Fund Direct-Growth
0.50%
-63156
-0.40%
-0.46%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.14%
27515
0.03%
0.03%
Bandhan Small Cap Fund Direct-Growth
0.53%
10000
-0.11%
-0.17%
Samco Multi Cap Fund Direct-Growth
0.00%
-4170
-0.10%
-0.34%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.53%
-2718
-0.09%
-0.09%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.31%
-22
-0.04%
-0.04%
Groww Nifty Total Market Index Fund Direct - Growth
0.02%
-6
0.00%
0.00%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
-3
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
2
0.00%
0.00%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
1.17%
0
-0.16%
-0.24%
WhiteOak Capital Balanced Advantage Fund Direct - Growth
0.12%
0
-0.02%
-0.03%
ICICI Prudential Multicap Fund Direct Plan-Growth
0.00%
0
0.00%
0.00%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
1.03%
0
-0.11%
0.08%
ITI Pharma and Healthcare Fund Direct - Growth
0.82%
0
-0.10%
-0.31%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Samco Active Momentum Fund Direct - Growth
0.00%
0
0.00%
0.00%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
0.73%
0
-0.10%
-0.13%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.54%
0
-0.07%
-0.10%
WhiteOak Capital Balanced Hybrid Fund Direct - Growth
0.17%
0
-0.03%
-0.05%
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
0.31%
0
-0.05%
-0.07%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.29%
0
-0.05%
-0.08%
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth
0.02%
0
-0.01%
-0.01%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.23%
0
-0.05%
-0.07%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.70%
0
-0.12%
-0.19%

Technical Indicators

RSI(14)
Neutral
31.15
ATR(14)
Less Volatile
15.46
STOCH(9,6)
Neutral
28.20
STOCH RSI(14)
Neutral
55.06
MACD(12,26)
Bearish
-1.11
ADX(14)
Strong Trend
30.94
UO(9)
Bearish
51.09
ROC(12)
Downtrend And Accelerating
-5.47
WillR(14)
Neutral
-78.69
Bearish
5
Neutral
3
Bullish
1
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Price & Volume Screeners
Candlestick Screeners
Technical Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104